Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Abbott India Ltd. Share Price
Day's Range
Day's Range
Low
₹28,455.00
High
₹28,905.00
Price Summary
| Previous Close | ₹28,690.00 |
|---|---|
| Day's Range | ₹28,455.00 - ₹28,905.00 |
| Open | ₹28,905.00 |
| 52 Week Range | ₹25,150.00 - ₹35,310.00 |
| Volume | 20,311 |
| Market Cap | ₹0.06 |
| Previous Close | ₹28,735.45 |
|---|---|
| Day's Range | ₹28,485.00 - ₹29,250.00 |
| Open | ₹29,018.85 |
| 52 Week Range | ₹25,164.00 - ₹35,280.00 |
| Volume | 909 |
| Market Cap | ₹0.06 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 5,834.15 |
|---|---|
| Market Cap (₹ in Mn) | 0.06 |
| Dividend Yield(%) | 2.28 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | 0.00 |
| P/E Ratio | 8.42 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | 13.37 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 49.12 |
| Trade Value ( ₹ in Lacs) | 261.17 |
|---|---|
| Market Cap (₹ in Mn) | 0.06 |
| Dividend Yield(%) | 2.28 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | 0.00 |
| P/E Ratio | 8.42 |
| Book Value(₹) | 0.00 |
| PAT Margin (%) | 13.37 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 49.12 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 64091.5 | 16045.9 |
| Expenses | N/A | N/A |
| PBT | 18869.5 | 4827.1 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 14144.4 | 3670.4 |
About Abbott India Ltd.
| Founded | 1944 |
|---|---|
| Managing Director | Kartik Rajendran |
| NSE Symbol | ABBOTINDIA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,68,842.05 | 1,954.05 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,93,859.76 | 7,312.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,92,686.75 | 5,027.80 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,27,682.21 | 8,928.05 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,12,593.44 | 1,393.75 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,082.03 | 1,113.60 | 835.50 - 835.50 |
| Lupin Ltd. | 1,09,553.48 | 2,400.95 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,05,607.20 | 2,561.70 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,05,473.64 | 1,085.00 | 903.00 - 903.00 |
| Dr. Reddy's Laboratories Ltd. | 97,364.93 | 1,166.50 | 1,148.40 - 1,148.40 |
No Records Found
Latest News
Abbott India informs about press release
Abbott India informs about notice of postal ballot
Eris Lifesciences informs about board meeting
Eris Lifesciences has informed that a Meeting of the Board of Directors of the Company is scheduled on Wednesday, July 29, 2026, to, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended June 30, 2026. Further, as informed by them vide letter dated June 26, 2026, the trading window has been already closed from July 01, 2026, and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015, and Policy on ‘Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company’.
The above information is a part of company’s filings submitted to BSE.
Rainbow Children’s Medicare informs about ESG rating
Pursuant to Regulation 30 of the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Rainbow Children’s Medicare has informed that CRISIL ESG Rating & Analytics (‘CRISIL ESG’) has on a voluntary basis assessed the overall Environmental, Social and Governance (ESG) and has assigned an ESG rating of 61 and a Core ESG rating of 73, based on disclosures for FY 2025-26, on July 22, 2026. The ESG rating of 61 reflects an improvement from ‘Adequate’ to ‘Strong’ ESG rating assigned to the Company for FY 2024-25 and FY 2023-24. The Company has not engaged CRISIL ESG for ESG Ratings. CRISIL ESG has independently prepared the report based on data pertaining to FY 2025-26 for the Company available in public domain.
The above information is a part of company’s filings submitted to BSE.
Amwill Health Care informs about newspaper publication
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Abbott India Ltd. is ₹28,690.00 as of 2026-07-23.
The market capitalisation of Abbott India Ltd. is ₹61,060.83 as of 2026-07-23.
The 1-year return of Abbott India Ltd. is -6,045.00% as of 2026-07-23.
The P/E ratio of Abbott India Ltd. is 35.49 as of 2026-07-24.
The 52-week high and low of Abbott India Ltd. are ₹35,310.00 and ₹25,150.00, respectively, as of 2026-07-23.
People Also Ask
Abbott India Ltd. provides an extensive portfolio of science-based nutritional products, diagnostic tools, and branded generic pharmaceuticals. The company holds a massive market presence in gastroenterology, women's health, specialised metabolic medications, and trusted over-the-counter medical solutions.
Abbott India Ltd. collaborates by extensively training healthcare professionals on new medical therapies and diagnostic technologies. The firm partners with large hospital networks to supply advanced laboratory diagnostic equipment and ensures important medical nutrition reaches specialised patient care units.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
